Limited joint mobility (LJM) in elderly subjects with type II diabetes mellitus

Archives of Gerontology and Geriatrics

Volumn 53, Issue 2, 2011, Pages 135-140

  Abate, Michele ^a   Schiavone, Cosima ^a   Pelotti, Patrizia ^b   Salini, Vincenzo ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Aging of diabetics; Diabetes; Joint mobility; Tendons in diabetic elderly; Ultrasonographic evaluation of joint mobility

Indexed keywords

ADVANCED GLYCATION END PRODUCT; COLLAGEN; GLUCOSE;

ACHILLES TENDON; AGED; ANKLE; ARTICLE; CONTROLLED STUDY; CROSS LINKING; ECHOGRAPHY; ELBOW FLEXION; FEMALE; GLYCEMIC CONTROL; GONIOMETRY; HIP; HUMAN; JOINT LIMITATION; JOINT MOBILITY; KNEE FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATELLA TENDON; PRIORITY JOURNAL; RANGE OF MOTION; RISK ASSESSMENT; SHOULDER;

ADULT; AGED; AGING; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; JOINT DISEASES; JOINTS; MALE; RANGE OF MOTION, ARTICULAR; SEVERITY OF ILLNESS INDEX;

EID: 79960103186     PISSN: 01674943     EISSN: 18726976     Source Type: Journal    
DOI: 10.1016/j.archger.2010.09.011     Document Type: Article

References (83)

1. ADA (American Diabetes Association) Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl. 1):S62-S69.
2. Arkkila P.E., Kantola I.M., Viikari J.S. Limited joint mobility in non-insulin-dependent diabetic (NIDDM) patients: correlation to control of diabetes, atherosclerotic vascular disease, and other diabetic complications. J. Diabetes Complications 1997, 11:208-217.
3. Balci N., Balci M.K., Tuzuner S. Shoulder adhesive capsulitis and shoulder range of motion in type II diabetes mellitus: association with diabetic complications. J. Diabetes Complications 1999, 13:135-140.
4. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., Kislinger T., Stern D.M., Schmidt A.M., De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002, 105:816-822.
5. Boone D.C., Azen S.P. Normal range of motion of joints in male subjects. J. Bone Joint Surg. Am. 1979, 61:756-759.
6. Chen H., Yao X.F., Emura S., Shoumura S. Morphological changes of skeletal muscle, tendon and periosteum in the senescence-accelerated mouse (SAMP6): a murine model for senile osteoporosis. Tissue Cell 2006, 38:325-335.
7. Crispin J.C., Alcocer-Varela J. Rheumatologic manifestations of diabetes mellitus. Am. J. Med. 2003, 114:753-757.
8. D'Ambrogi E., Giurato L., D'Agostino M.A., Giacomozzi C., Macellari V., Caselli A., Uccioli L. Contribution of plantar fascia to the increased forefoot pressures in diabetic patients. Diabetes Care 2003, 26:1525-1529.
9. DeGroot J. The AGE of the matrix: chemistry, consequence and cure. Curr. Opin. Pharmacol. 2004, 4:301-305.
10. Dutta U., Cohenford M.A., Guha M., Dain J.A. Non-enzymatic interactions of glyoxylate with lysine, arginine, and glucosamine: a study of advanced non-enzymatic glycation like compounds. Bioorg. Chem. 2007, 35:11-24.
11. Escalante A., Lichtenstein M.J., Hazuda H.P. Determinants of shoulder and elbow flexion range: results from the San Antonio Longitudinal Study of Aging. Arthritis Care Res. 1999, 12:277-286.
12. Forbes J.M., Thallas V., Thomas M.C., Founds H.W., Burns W.C., Jerums G., Cooper M.E. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 2003, 17:1762-1764.
13. Franke S., Sommer M., Ruster C., Bondeva T., Marticke J., Hofmann G., Hein G., Wolf G. Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells. Arthritis Res. Ther. 2009, 11:R136.
14. Friedman L., Finlay K., Jurriaans E. Ultrasound of the knee. Skeletal Radiol. 2001, 30:361-377.
15. Frost D., Beischer W. Limited joint mobility in type 1 diabetic patients: associations with microangiopathy and subclinical macroangiopathy are different in men and women. Diabetes Care 2001, 24:95-99.
16. Giacomozzi C., Caselli A., Macellari V., Giurato L., Lardieri L., Uccioli L. Walking strategy in diabetic patients with peripheral neuropathy. Diabetes Care 2002, 25:1451-1457.
17. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
18. Goldspink G. Loss of muscle strength during aging studied at the gene level. Rejuven. Res. 2007, 10:397-405.
19. Grgic A., Rosenbloom A.L., Weber F.T., Giordano B., Malone J.I., Shuster J.J. Joint contracture-common manifestation of childhood diabetes mellitus. J. Pediatr. 1976, 88:584-588.
20. Grimston S.K., Nigg B.M., Hanley D.A., Engsberg J.R. Differences in ankle joint complex range of motion as a function of age. Foot Ankle 1993, 14:215-222.
21. Haitas B., Jones D.B., Ting A., Turner R.C. Diabetic retinopathy and its association with limited joint mobility. Horm. Metab. Res. 1986, 18:765-767.
22. Harvey L., Herbert R., Crosbie J. Does stretching induce lasting increases in joint ROM? A systematic review. Physiother. Res. Int. 2002, 7:1-13.
23. Hofmann M.A., Drury S., Hudson B.I., Gleason M.R., Qu W., Lu Y., Lalla E., Chitnis S., Monteiro J., Stickland M.H., Bucciarelli L.G., Moser B., Moxley G., Itescu S., Grant P.J., Gregersen P.K., Stern D.M., Schmidt A.M. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 2002, 3:123-135.
24. Hudson B.I., Bucciarelli L.G., Wendt T., Sakaguchi T., Lalla E., Qu W., Lu Y., Lee L., Stern D.M., Naka Y., Ramasamy R., Yan S.D., Yan S.F., D'Agati V., Schmidt A.M. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch. Biochem. Biophys. 2003, 419:80-88.
25. Ippolito E., Natali P.G., Postacchini F., Accinni L., De Martino C. Morphological, immunochemical, and biochemical study of rabbit Achilles tendon at various ages. J. Bone Joint Surg. Am. 1980, 62:583-598.
26. Jennings A.M., Milner P.C., Ward J.D. Hand abnormalities are associated with the complications of diabetes in type 2 diabetes. Diabet. Med. 1989, 6:43-47.
27. Kass D.A., Shapiro E.P., Kawaguchi M., Capriotti A.R., Scuteri A., DeGroof R.C., Lakatta E.G. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001, 104:1464-1470.
28. Kjaer M. Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol. Rev. 2004, 84:649-698.
29. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 1997, 272:17810-17814.
30. Lindsay J.R., Kennedy L., Atkinson A.B., Bell P.M., Carson D.J., McCance D.R., Hunter S.J. Reduced prevalence of limited joint mobility in type 1 diabetes in a U.K. clinic population over a 20-year period. Diabetes Care 2005, 28:658-661.
31. Lu Y.C., Wang P.W., Liu R.T., Tung S.C., Chien W.Y., Hung S.L., Chen M. Limited joint mobility of the hand: prevalence and relation to chronic complications in non-insulin-dependent diabetes mellitus patients. J. Formos. Med. Assoc. 1993, 92:139-143.
32. Macedo L.G., Magee D.J. Differences in range of motion between dominant and nondominant sides of upper and lower extremities. J. Manipul. Physiol. Ther. 2008, 31:577-582.
33. Macedo L.G., Magee D.J. Effects of age on passive range of motion of selected peripheral joints in healthy adult females. Physiother. Theory Pract. 2009, 25:145-164.
34. McCarthy A.D., Etcheverry S.B., Bruzzone L., Lettieri G., Barrio D.A., Cortizo A.M. Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol. 2001, 2:16.
35. Metz T.O., Alderson N.L., Thorpe S.R., Baynes J.W. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch. Biochem. Biophys. 2003, 419:41-49.
36. Montana E., Rozadilla A., Nolla J.M., Gomez N., Escofet D.R., Soler J. Microalbuminuria is associated with limited joint mobility in type I diabetes mellitus. Ann. Rheum. Dis. 1995, 54:582-586.
37. Moosikasuwan J.B., Miller T.T., Burke B.J. Rotator cuff tears: clinical, radiographic, and US findings. Radiographics 2005, 25:1591-1607.
38. Morvan G., Busson J., Wybier M., Mathieu P. Ultrasound of the ankle. Eur. J. Ultrasound 2001, 14:73-82.
39. Nah S.S., Choi I.Y., Lee C.K., Oh J.S., Kim Y.G., Moon H.B., Yoo B. Effects of advanced glycation end products on the expression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes. Rheumatology (Oxford) 2008, 47:425-431.
40. Narici M.V., Maganaris C.N. Plasticity of the muscle-tendon complex with disuse and aging. Exerc. Sport Sci. Rev. 2007, 35:126-134.
41. Narici M.V., Maffulli N., Maganaris C.N. Ageing of human muscles and tendons. Disabil. Rehabil. 2008, 30:1548-1554.
42. Nigg B.M., Fisher V., Allinger T.L., Ronsky J.R., Engsberg J.R. Range of motion of the foot as a function of age. Foot Ankle 1992, 13:336-343.
43. O'Grady M., Fletcher J., Ortiz S. Therapeutic and physical fitness exercise prescription for older adults with joint disease: an evidence-based approach. Rheum. Dis. Clin. North Am. 2000, 26:617-646.
44. Pageon H., Techer M.P., Asselineau D. Reconstructed skin modified by glycation of the dermal equivalent as a model for skin aging and its potential use to evaluate anti-glycation molecules. Exp. Gerontol. 2008, 43:584-588.
45. Pal B., Anderson J., Dick W.C., Griffiths I.D. Limitation of joint mobility and shoulder capsulitis in insulin- and non-insulin-dependent diabetes mellitus. Br. J. Rheumatol. 1986, 25:147-151.
46. Papanas N., Maltezos E. The diabetic hand: a forgotten complication? J. Diabetes Complications 2009, 24:154-162.
47. Petrulewicz-Salamon I. The influence of diabetes mellitus on joint mobility. Orthop. Traumatol. Rehabil. 2006, 8:555-565.
48. Radford J.A., Burns J., Buchbinder R., Landorf K.B., Cook C. Does stretching increase ankle dorsiflexion range of motion? A systematic review. Br. J. Sports Med. 2006, 40:870-875.
49. Rahbar S. Novel inhibitors of glycation and AGE formation. Cell Biochem. Biophys. 2007, 48:147-157.
50. Ramchurn N., Mashamba C., Leitch E., Arutchelvam V., Narayanan K., Weaver J., Hamilton J., Heycock C., Saravanan V., Kelly C. Upper limb musculoskeletal abnormalities and poor metabolic control in diabetes. Eur. J. Intern. Med. 2009, 20:718-721.
51. Rao S., Saltzman C., Yack H.J. Ankle ROM and stiffness measured at rest and during gait in individuals with and without diabetic sensory neuropathy. Gait Posture 2006, 24:295-301.
52. Reeves N.D., Narici M.V., Maganaris C.N. Myotendinous plasticity to ageing and resistance exercise in humans. Exp. Physiol. 2006, 91:483-498.
53. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., Giacovelli G., Henrotin Y., Dacre J.E., Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256.
54. Reiser K., Summers P., Medrano J.F., Rucker R., Last J., McDonald R. Effects of elevated circulating IGF-1 on the extracellular matrix in " high-growth" C57BL/6J mice. Am. J. Physiol. 1996, 271:R696-R703.
55. Roach K.E., Miles T.P. Normal hip and knee active range of motion: the relationship to age. Phys. Ther. 1991, 71:656-665.
56. Rosenbloom A.L. Skeletal and joint manifestations of childhood diabetes. Pediatr. Clin. North Am. 1984, 31:569-589.
57. Rosenbloom A.L. Limitation of finger joint mobility in diabetes mellitus. J. Diabetes Complications 1989, 3:77-87.
58. Rosenbloom A.L. Limited joint mobility in insulin dependent childhood diabetes. Eur. J. Pediatr. 1990, 149:380-388.
59. Rosenbloom A.L., Silverstein J.H. Connective tissue and joint disease in diabetes mellitus. Endocrinol. Metab. Clin. North Am. 1996, 25:473-483.
60. Rosenbloom A.L., Hunt S.S., Rosenbloom E.K., Maclaren N.K. Ten-year prognosis of impaired glucose tolerance in siblings of patients with insulin-dependent diabetes. Diabetes 1982, 31:385-387.
61. Rutten M.J., Jager G.J., Blickman J.G. From the RSNA refresher courses: US of the rotator cuff: pitfalls, limitations, and artifacts. Radiographics 2006, 26:589-604.
62. Saito M., Fujii K., Soshi S., Tanaka T. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos. Int. 2006, 17:986-995.
63. Salsich G.B., Brown M., Mueller M.J. Relationships between plantar flexor muscle stiffness, strength, and range of motion in subjects with diabetes-peripheral neuropathy compared to age-matched controls. J. Orthop. Sports Phys. Ther. 2000, 30:473-483.
64. Santilli F., Bucciarelli L., Noto D., Cefalu A.B., Davi V., Ferrante E., Pettinella C., Averna M.R., Ciabattoni G., Davì G. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic. Biol. Med. 2007, 43:1255-1262.
65. Sauseng S., Kastenbauer T., Irsigler K. Limited joint mobility in selected hand and foot joints in patients with type 1 diabetes mellitus: a methodology comparison. Diabetes Nutr. Metab. 2002, 15:1-6.
66. Savas S., Koroglu B.K., Koyuncuoglu H.R., Uzar E., Celik H., Tamer N.M. The effects of the diabetes related soft tissue hand lesions and the reduced hand strength on functional disability of hand in type 2 diabetic patients. Diabetes Res. Clin. Pract. 2007, 77:77-83.
67. Schulte L., Roberts M.S., Zimmerman C., Ketler J., Simon L.S. A quantitative assessment of limited joint mobility in patients with diabetes. Goniometric analysis of upper extremity passive range of motion. Arthritis Rheum. 1993, 36:1429-1443.
68. Sharman M.J., Cresswell A.G., Riek S. Proprioceptive neuromuscular facilitation stretching: mechanisms and clinical implications. Sports Med. 2006, 36:929-939.
69. Shinabarger N.I. Limited joint mobility in adults with diabetes mellitus. Phys. Ther. 1987, 67:215-218.
70. Smith L.L., Burnet S.P., McNeil J.D. Musculoskeletal manifestations of diabetes mellitus. Br. J. Sports Med. 2003, 37:30-35.
71. Stanziano D.C., Roos B.A., Perry A.C., Lai S., Signorile J.F. The effects of an active-assisted stretching program on functional performance in elderly persons: a pilot study. Clin. Interv. Aging 2009, 4:115-120.
72. Starkman H.S., Gleason R.E., Rand L.I., Miller D.E., Soeldner J.S. Limited joint mobility (LJM) of the hand in patients with diabetes mellitus: relation to chronic complications. Ann. Rheum. Dis. 1986, 45:130-135.
73. Steenvoorden M.M., Toes R.E., Ronday H.K., Huizinga T.W., DeGroot J. RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro. Clin. Exp. Rheumatol. 2007, 25:740-742.
74. Thornalley P.J., Minhas H.S. Rapid hydrolysis and slow alpha,beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochem. Pharmacol. 1999, 57:303-307.
75. Valencia J.V., Weldon S.C., Quinn D., Kiers G.H., DeGroot J., TeKoppele J.M., Hughes T.E. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal. Biochem. 2004, 324:68-78.
76. Vasan S., Zhang X., Zhang X., Kapurniotu A., Bernhagen J., Teichberg S., Basgen J., Wagle D., Shih D., Terlecky I., Bucala R., Cerami A., Egan J., Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996, 382:275-278.
77. Vazzana N., Santilli F., Cuccurullo C., Davi G. Soluble forms of RAGE in internal medicine. Intern. Emerg. Med. 2009, 4:389-401.
78. Voziyan P.A., Khalifah R.G., Thibaudeau C., Yildiz A., Jacob J., Serianni A.S., Hudson B.G. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J. Biol. Chem. 2003, 278:46616-46624.
79. Wu X., Mounier V.M. Enzymatic deglycation of proteins. Arch. Biochem. Biophys. 2003, 419:16-24.
80. Yamagishi S., Nakamura K., Matsui T., Ueda S., Fukami K., Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin. Invest. Drugs 2008, 17:983-996.
81. Yang S., Litchfield J.E., Baynes J.W. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch. Biochem. Biophys. 2003, 412:42-46.
82. Ytterberg S.R., Mahowald M.L., Krug H.E. Exercise for arthritis. Baillieres Clin. Rheumatol. 1994, 8:161-189.
83. Zerkak D., Dougados M. The use of glucosamine therapy in osteoarthritis. Curr. Rheumatol. Rep. 2004, 6:41-45.